86859-00-9Relevant articles and documents
USE OF SILVER(I) COMPLEXES AS ANTICANCER AGENTS
-
Paragraph 0186, (2017/09/08)
The present invention relates to the use of silver(I) monophosphine complexes as Active Pharmaceutical Ingredients (API's), including anticancer agents, for the treatment, diagnosis and/or prevention of cancer. The present invention also relates to pharmaceutical compositions containing such complexes and further extends to a method of treating or diagnosing a subject/patient suffering from cancer.
Synthesis and characterization of some monomeric and dimeric silver(I)-phosphine complexes with N-donor bridging ligands
Sarkhel, Prashanta,Bhattacharjee, Suchandra,Sarkhel, Sejuti,Chakraborty, Surajit
, p. 1154 - 1157 (2013/01/14)
The monomeric complexes [Ag(PPh3)2]X (X = ClO 4 - or NO3) was synthesized by a metathesis reaction of [Ag2(PPh3)4(μ-SO4)] with BaX2 (where X = ClO4 - or NO3 -) in ethanol. The reactivity of [Ag(PPh3)2]X (where X = ClO4 - or NO3 -) with some potential N-donor bridging ligands viz. 4,4 bipyridine and pyrazine yielded dimeric complexes of the type [Ag2(PPh3) 4(μ-L-L)]X2 (where L-L = 4,4-bipyridine or pyrazine, and X = ClO4 - or NO3 -). All these complexes were characterized by infrared spectroscopy, conductivity measurements, cyclic voltammetry, 1H NMR, and electronic spectroscopy.
Syntheses and structures of silver(I) and palladium(II) complexes with ferrocenyl-phosphonodithiolate ligands
Wang, Xi-Ying,Shi, Hua-Tian,Ma, Qing,Zhang, Qian-Feng
, p. 32 - 36 (2010/05/02)
Coordinative interaction of [Ag(PPh3)2NO3] or [Pd(MeCN)2Cl2] with in situ-prepared Na[FcP-(OR)S 2] afforded 1 : 1 products [FcP(OR)S2Ag(PPh 3)2] (R = Me 1,
